A research group from Japan has developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA. This "Purecap" technique extracted up to 100% pure Cap2-type ...
Jul 5, 2023
0
34
Research by the University of Southampton into the effectiveness of COVID-19 vaccines in people with lymphoma has shown that repeated vaccination increases their ability to prevent infection from the virus, particularly after ...
Jul 3, 2023
0
113
Cambridge scientists have identified a signature in the blood that could help predict how well an individual will respond to vaccines. The discovery, published today in Nature Communications, may explain why, even among vulnerable ...
Jun 27, 2023
0
21
What scientists learned about the rare antibodies targeting SARS-CoV-2's Achilles' heel could help fine-tune our COVID-19 vaccine strategy for longer-lasting immunity.
Jun 26, 2023
0
39
At some point in their life, it's estimated that around 80% of people will be infected with the human papillomavirus (HPV).
Jun 16, 2023
0
94
Despite some of the most successful international vaccination campaigns in history, the poliovirus continues to circulate around the world, posing a threat of neurological damage and even paralysis to anyone who is not vaccinated.
Jun 14, 2023
1
48
Better access to vaccines could have prevented more than 50% of COVID-19 deaths in 20 lower income countries, according to a new paper in Nature Communications co-authored by Northeastern professor Alessandro Vespignani.
Jun 13, 2023
0
134
After having successfully tested a mucosal vaccine against coronavirus in animals just months ago, Berlin scientists have now further developed their live SARS-CoV-2 vaccine. Researchers at Freie Universität Berlin have ...
Jun 13, 2023
0
100
Scientists have now made substantial progress in predicting the path that COVID-19 will take in patients, finding sets of biological features that are associated with the course and severity of COVID-19. The findings were ...
Jun 13, 2023
0
9
The VLA1553 vaccine candidate for chikungunya disease was generally well tolerated and produced an immune response in 99% (263/266) of participants, according to a phase 3 randomized controlled trial published in The Lancet.
Jun 12, 2023
0
40
